Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
TIFAB is a protein homologous to TIFA, but with truncated N- and C- terminal regions. It binds directly to TIFA and inhibits TIFA-mediated activation of NF-κB—a key pathway in innate immunity and inflammation—by blocking the formation of TIFA-TRAF6 signaling complexes[1][3]. While TIFA itself is a hub for immune activation and DNA damage response, TIFAB serves as a negative regulator, modulating the extent and duration of these signals. Thus, TIFAB is best thought of as a protein modulator within immune signaling networks rather than as a classical receptor, drug target, or enzyme[1][3].
Inhibits TIFA-triggered TRAF6 signaling and downstream NF-κB activation by binding to TIFA and blocking its oligomerization or activity[1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on TRAF-interacting protein with FHA domain-containing protein B (TIFAB).